-
Sector Analysis
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in IgA Nephropathy (Berger’s Disease) Therapeutics. • In 2025, there were 102,155 incident cases of Berger's disease in the 16 countries covered in GlobalData’s epidemiology forecast. • Berger's disease is primarily managed with blood pressure medication like ACE inhibitors or ARBs to protect the kidneys. For high-risk patients, corticosteroids and newer targeted therapies are also available to slow the disease's progression. • The Berger's disease pipeline holds...
-
Sector Analysis
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future Competitive Landscape
Why Does the Global Reflux Esophagitis Therapeutics Market Matter? Reflux esophagitis and gastroesophageal reflux disease (GERD) represent a significant global therapeutic market, with treatment typically involving lifestyle modifications, pharmacological therapies, and, in selected cases, surgical or endoscopic interventions. GlobalData’s Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Market View provides a data-driven assessment of the current and future competitive landscape, combining Pharma Intelligence Center data with analyst expertise. In 2025, there were 308.98 million 12-month total diagnosed prevalent cases of GERD across...
-
Sector Analysis
Postpartum Depression (PPD): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Postpartum Depression (PPD) Therapeutics. In 2025, there were 10.89 million prevalent cases of PPD across the 16 countries covered in GlobalData’s epidemiology forecast. PPD is typically managed with psychotherapy (CBT or interpersonal therapy) and antidepressants, most commonly SSRIs, tailored to breastfeeding considerations and patient preferences, alongside practical supports such as sleep and family assistance. For moderate-to-severe illness, faster-acting neuroactive steroid treatments include IV brexanolone (a 60-hour...
-
Sector Analysis
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
Why Does Hepatocellular Carcinoma Epidemiology Matter? Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for approximately 90% of primary liver cancers. Understanding the size and characteristics of the HCC patient population is important for assessing disease burden and planning therapeutic strategies. HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide. This epidemiology model provides a 10-year forecast of diagnosed incident cases, five-year diagnosed prevalent cases, and all-time diagnosed prevalent...
-
Sector Analysis
Overweight and Obesity: Epidemiology Report and Forecast to 2035
Why Does Overweight and Obesity Epidemiology Matter? Overweight and obesity are major health conditions associated with excess body fat, metabolic dysfunction, chronic inflammation, and comorbidities including diabetes and cardiovascular disease. Understanding the size and characteristics of these populations is essential for healthcare and life sciences companies developing products and commercial strategies. This report provides a comprehensive epidemiological assessment across the seven major markets (7MM), covering the US, France, Germany, Italy, Spain, the UK, and Japan. You can use this report...
-
Sector Analysis
Against the Clock: the Bundibugyo Ebola Outbreak
Research into new Ebola vaccines and therapeutics, ranging from prophylaxis to post-exposure prophylaxis treatment candidates, are being fast-tracked, using similar mechanisms to fast-tracked COVID-19 trials. Even so, there are legitimate concerns that the Bundibugyo strain of the Ebola virus is moving faster than the response of technology developers, regulators, governments, and international organizations.
-
Sector Analysis
Hepatitis C Virus: Epidemiology Report and Forecast to 2035
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue,...
-
Sector Analysis
Epilepsy: Epidemiology Report and Forecast to 2035
Why Does Epilepsy Epidemiology Matter? Epilepsy is one of the most widespread neurological disorders globally, characterized by recurrent, unpredictable seizures caused by abnormal electrical activity in the brain. Understanding the size and composition of the diagnosed patient population is critical for assessing future healthcare and treatment needs. In the seven major markets (7MM), active diagnosed prevalent cases of epilepsy are forecast to increase from 6.2 million in 2025 to 6.5 million in 2035, representing an annual growth rate (AGR) of...
-
Company Insights
Catalyst Monitor: Q3 2026 Outlook
This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q3 2026. GlobalData’s latest report, “Catalyst Monitor Q3 2026”, delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, Phase III trial results, PDUFA dates, and regulatory filings. The report covers 11 significant catalyst events that are expected to occur in Q3 2026. Some of the catalysts covered in the report, include...
-
Sector Analysis
New Drug Approvals and Their Contract Manufacture: 2026 Edition
This report is the 16th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how the US onshoring push is creating billion-dollar manufacturing investments.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.